Contract development and manufacturing organization (CDMO) Saneca Pharma is driving forward with new research and development initiatives for the manufacture of active pharmaceutical ingredients (APIs) following a €1.5 million grant from the Slovak Ministry of Education, Science, Research and Sport.
With over 70 years of opiate fully backward integrated production we can guarantee the highest quality and full control over the final product delivered to our customers.More Info
Slovakia-based contract development and manufacturing organisation (CDMO) Saneca Pharma has secured an agreement with Italian pharmaceutical company Menarini Group to deliver controlled release pellets for one of its products. As part of the five-year supply agreement, Saneca Pharma will be investing in its facility in Hlohovec, Slovakia, to increase the scale at which it can…
Saneca Pharma will be present at the upcoming DCAT Week with Anthony Sheehan (CEO) and Jan Baťka (API Sales Director). Please contact firstname.lastname@example.org should you wish to arrange a meeting.
Do you want to attend?
+421 33 736 1111, email@example.com
The European pharmaceutical industry has grown exponentially over the last ten years. As a result, pharmaceutical manufacturers have faced a number of challenges as droughts, escalating costs, downward price pressure from governments and the need for faster turnaround times to bring new drugs to the market.